Abstract
Background:Osmotic agents, such as inhaled dry powder mannitol, may increase mucociliary clearance by rehydrating the airway surface liquid and thus act as disease-modifying treatments in cystic fibrosis (CF). This is...
Highlights
Osmotic agents, such as inhaled dry powder mannitol, may increase mucociliary clearance by rehydrating the airway surface liquid and act as disease-modifying treatments in cystic fibrosis (CF)
forced expiratory volume in 1 s (FEV1) and the secondary outcome measures were analysed on a measurement scale and the results presented as mean differences
Forty-five children were recruited to the study, 38 of whom underwent an airway challenge with inhaled mannitol
Summary
Osmotic agents, such as inhaled dry powder mannitol, may increase mucociliary clearance by rehydrating the airway surface liquid and act as disease-modifying treatments in cystic fibrosis (CF). This is the first therapeutic trial of inhaled mannitol in children with CF; it was compared with recombinant human deoxyribonuclease (rhDNase), the current best established mucolytic treatment. Subjects underwent an initial bronchial provocation challenge with dry powder mannitol Those children with a negative challenge were randomly allocated to one of three consecutive 12-week treatment blocks (inhaled mannitol alone, nebulised rhDNase alone and mannitol + rhDNase). A number of secondary outcome measures were studied.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
